Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Blood Cancer ; 65(12): e27420, 2018 12.
Article in English | MEDLINE | ID: mdl-30151977

ABSTRACT

BACKGROUND: Painful events are the leading cause of hospitalizations for patients with sickle cell disease. Individualized pain plans targeting patient-specific maximum opioid dosing may shorten hospitalization length and are recommended by national guidelines. Prior to implementing individualized sickle cell pain plans, we tested the hypothesis that a shorter time to achieve a maximum opioid dose would improve hospitalization outcomes. PROCEDURE: Two-year IRB-approved, retrospective study of pediatric patients admitted for vaso-occlusive crisis (VOC). We recorded the emergency department admission time, order entry time for the maximum opioid dose during the hospitalization, and time of discharge orders.  We categorized patients as infrequent if they required <3 admissions for VOC over two years and patients as frequent if they required ≥3 admissions for VOC over two years. To account for multiple admissions, generalized linear modeling was performed. RESULTS: We identified 236 admissions for acute pain observed in 108 patients. Achieving an earlier maximum opioid dose was significantly associated with shorter length of hospitalization for frequent and infrequent pain patients (both P ≤ 0.0001). As total hospitalization length can be impacted by the time a maximum opioid order was placed, we also analyzed hospitalization length after the maximum opioid order was placed. Frequent pain patients who achieved earlier analgesia had a significantly shorter hospitalization from the time the maximum opioid order was placed (P = 0.03) while no association was found for infrequent pain patients (P = 0.84). CONCLUSIONS: Early achievement of maximum analgesia improved hospitalization outcomes and warrant further investigation in prospective studies of individualized pain plans.


Subject(s)
Acute Pain/drug therapy , Acute Pain/etiology , Analgesics, Opioid/administration & dosage , Anemia, Sickle Cell/complications , Pain Management/methods , Adolescent , Child , Female , Hospitalization , Humans , Male , Retrospective Studies
2.
J Am Med Inform Assoc ; 20(e2): e221-5, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23886923

ABSTRACT

Large-scale biorepositories that couple biologic specimens with electronic health records containing documentation of phenotypic expression can accelerate scientific research and discovery. However, differences between those subjects who participate in biorepository-based research and the population from which they are drawn may influence research validity. While an opt-out approach to biorepository-based research enhances inclusiveness, empirical research evaluating voluntariness, risk, and the feasibility of an opt-out approach is sparse, and factors influencing patients' decisions to opt out are understudied. Determining why patients choose to opt out may help to improve voluntariness, however there may be ethical and logistical challenges to studying those who opt out. In this perspective paper, the authors explore what is known about research based on the opt-out model, describe a large-scale biorepository that leverages the opt-out model, and review specific ethical and logistical challenges to bridging the research gaps that remain.


Subject(s)
Biological Specimen Banks/ethics , Biomedical Research/ethics , Electronic Health Records/ethics , Patient Acceptance of Health Care , Biomedical Research/methods , Humans , Informed Consent
3.
Per Med ; 10(4)2013 Jun.
Article in English | MEDLINE | ID: mdl-24416062

ABSTRACT

AIM: In this study, we sought to assess patient awareness and perceptions of an opt-out biorepository. MATERIALS & METHODS: We conducted exit interviews with adult patients and parents of pediatric patients having their blood drawn as part of their clinical care at Vanderbilt University Medical Center (TN, USA). RESULTS: 32.9% of all patients and parents of pediatric patients report having heard of the opt-out biorepository, while 92.4% approve of this research effort based on a brief description. Awareness that leftover blood could be used for research increased among adult patients during the study period, from 34.3 to 50.0%. CONCLUSION: These findings will inform ongoing assessments of the suitability of opt-out and opt-in methods as alternatives to written informed consent for inclusion in a biorepository.

4.
PLoS One ; 7(2): e31024, 2012.
Article in English | MEDLINE | ID: mdl-22363539

ABSTRACT

YAC128 Huntington's disease (HD) transgenic mice accumulate less manganese (Mn) in the striatum relative to wild-type (WT) littermates. We hypothesized that Mn and mutant Huntingtin (HTT) would exhibit gene-environment interactions at the level of neurochemistry and neuronal morphology. Twelve-week-old WT and YAC128 mice were exposed to MnCl(2)-4H(2)O (50 mg/kg) on days 0, 3 and 6. Striatal medium spiny neuron (MSN) morphology, as well as levels of dopamine (DA) and its metabolites (which are known to be sensitive to Mn-exposure), were analyzed at 13 weeks (7 days from initial exposure) and 16 weeks (28 days from initial exposure). No genotype-dependent differences in MSN morphology were apparent at 13 weeks. But at 16 weeks, a genotype effect was observed in YAC128 mice, manifested by an absence of the wild-type age-dependent increase in dendritic length and branching complexity. In addition, genotype-exposure interaction effects were observed for dendritic complexity measures as a function of distance from the soma, where only YAC128 mice were sensitive to Mn exposure. Furthermore, striatal DA levels were unaltered at 13 weeks by genotype or Mn exposure, but at 16 weeks, both Mn exposure and the HD genotype were associated with quantitatively similar reductions in DA and its metabolites. Interestingly, Mn exposure of YAC128 mice did not further decrease DA or its metabolites versus YAC128 vehicle exposed or Mn exposed WT mice. Taken together, these results demonstrate Mn-HD disease-toxicant interactions at the onset of striatal dendritic neuropathology in YAC128 mice. Our results identify the earliest pathological change in striatum of YAC128 mice as being between 13 to 16 weeks. Finally, we show that mutant HTT suppresses some Mn-dependent changes, such as decreased DA levels, while it exacerbates others, such as dendritic pathology.


Subject(s)
Dopamine/metabolism , Environmental Exposure , Huntington Disease/pathology , Manganese/toxicity , Neostriatum/pathology , Neurons/pathology , Animals , Dendrites/drug effects , Dendrites/metabolism , Dendrites/pathology , Genotype , Huntington Disease/genetics , Male , Manganese/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Multivariate Analysis , Neostriatum/drug effects , Neurons/drug effects , Neurons/metabolism
5.
Neurotoxicology ; 32(6): 896-906, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21641932

ABSTRACT

Gender differences in sensitivity and toxicokinetics of multiple metals have been identified in humans. A recent study suggested that young girls performed worse on intellectual exams than young boys exposed to manganese (Mn) in the environment. Animal studies have shown that Mn exposure causes differential effects on behavior in male compared to female mice. We hypothesized that in response to Mn exposure striatal Mn accumulation and/or striatal medium spiny neuron (MSN) morphology show gender-dependent effects. We evaluated the contribution of gender to neuropathology by examining striatal MSN morphology in male and female mice exposed to Mn. We found that gender played a significant role in alterations of striatal MSN morphology in mice exposed to Mn. Gender-dependent changes were strongest when striatal Mn levels were elevated 24h following the final Mn exposure. Nevertheless, gender-dependent alterations in neuron morphology were still present 3 weeks after the final Mn exposure. Gender differences in neuron morphology were not due to differential striatal Mn accumulation between genders. We conclude that although gender does not affect striatal Mn accumulation, MSN morphology is differentially sensitive to elevated Mn levels.


Subject(s)
Basal Ganglia/drug effects , Cell Shape/drug effects , Chlorides/toxicity , Environmental Pollutants/toxicity , Neurons/drug effects , Analysis of Variance , Animals , Basal Ganglia/metabolism , Basal Ganglia/pathology , Chlorides/metabolism , Dendrites/drug effects , Dendrites/pathology , Environmental Pollutants/metabolism , Female , Male , Manganese Compounds/metabolism , Mice , Neurons/metabolism , Neurons/pathology , Risk Assessment , Risk Factors , Sex Factors , Time Factors
6.
Curr Protoc Toxicol ; Chapter 12: Unit 12.16, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20401325

ABSTRACT

The study of dendritic length and spine density has become a standard in the analysis of neuronal abnormalities since a considerable number of neurological diseases have their foundation in alterations in these structures. One of the best ways to study possible alterations in neuronal morphometry is the use of Golgi impregnation. Introduced more than a century ago, it is still the standard and state-of-the-art technique for visualization of neuronal architecture. We successfully applied the Golgi method to mouse, rat, monkey and human brain tissues for studying both the normal and abnormal morphology of neurons. We were able to discover subtle morphological alterations in neuronal dendrites and dendritic spines in different brain areas. Although Golgi preparations can be examined by electronic microscopy, we used light microscopy and Neurolucida reconstruction to quantitatively explore the relationship between total dendritic length and spine density in different types of neurons. This review summarizes the methodology used to quantify neuronal abnormalities and discusses the utility of these techniques in different models of neurodegeneration.


Subject(s)
Brain/ultrastructure , Dendrites/ultrastructure , Histocytological Preparation Techniques/methods , Neurodegenerative Diseases/pathology , Animals , Dendritic Spines/ultrastructure , Humans , Purkinje Cells/ultrastructure
7.
World J Gastroenterol ; 13(39): 5277-81, 2007 Oct 21.
Article in English | MEDLINE | ID: mdl-17876901

ABSTRACT

Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritus, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9th and 10th infusions, she developed fever to a maximum of 38.3 centigrade with stable hemodynamic status despite medications. During 11th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8 centigrade, BP dropped to 95/43 mm Hg, pulse of 116/min and O(2) saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/adverse effects , Colorectal Neoplasms/drug therapy , Drug Hypersensitivity/diagnosis , Fever/chemically induced , Organoplatinum Compounds/adverse effects , Antineoplastic Agents/therapeutic use , Female , Fever/diagnosis , Humans , Hypotension/chemically induced , Hypotension/diagnosis , Middle Aged , Organoplatinum Compounds/therapeutic use , Oxaliplatin
SELECTION OF CITATIONS
SEARCH DETAIL
...